2026 Q1 -tulosraportti
UUTTA
7 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,95%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 24 | - | - | ||
| 93 | - | - | ||
| 96 | - | - | ||
| 100 | - | - | ||
| 72 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 711 451 | 2 711 451 | 0 | 0 |
| DCAR | 40 000 | 40 000 | 0 | 40 000 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 711 451 | 2 711 451 | 0 | 0 |
| DCAR | 40 000 | 40 000 | 0 | 40 000 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·16 min sittenOn the dot.
·22 min sitten · MuokattuUltimately, the price is probably driven by what the market expects going forward, and whether the company delivers better or worse than those expectations. I doubt that a "good piece of news" is necessarily enough if the market had already priced it in. And if the news just meets expectations, or disappoints even slightly, the stock can still be punished. So, in that sense, the market must also be willing to pay a higher and higher price every time new evidence for the case emerges. And right there, I think Novo will have a hard time with that in the short term. Not because the company is bad, but because confidence has been weakened, and because much of the positive news about obesity/GLP-1 has already been priced in before. I think the market will demand more than good headlines now. Real results will probably be needed: better earnings, better margins, less price pressure, stronger guidance and proof that the Wegovy pill doesn't just provide volume, but also profitable growth. Otherwise, it will be difficult to get the market to accept significantly higher prices again. It's probably also more about whether buyers are willing to be more and more aggressive and pay higher prices. And if many are sitting on large losses from the peak, the old levels can also become resistance, because people will want to get out when they get the chance. So I believe Novo can rise again (in the long term), but I don't think the market just gives them benefit of the doubt anymore. They need to prove the case in the numbers, not just in the narrative, and I doubt even more that they will do that in the short term. But well, what I'm saying is probably completely wrong, but we debate to become wiser, and that's just my actual statement on it
·13 min sittenCouldn't agree more. I believe the stock is undervalued, but I also believe it's the numbers that should drive the price and not hype. Facts on the table, and we will get the price increases Novo deserves. The last 2 years have created great uncertainty, understandably. As the numbers improve, the stock will also be unleashed more, but Novo needs to show something more. That said, the stock HAS risen significantly recently and there will be investors who believe 300 kr is a good place to let it go.- ·31 min sittenIt's trickling a bit early today, but it will, as usual, pick up in 12 min when US opens.
·1 t sittenExplanation requested: approx. 20 pct of the turnover of shares takes place on the American stock exchange. The rest takes place in DK. Why is it NOVO ADR that largely determines the price? Any good suggestions?- ·1 t sittenIt's a bit ''funny'' to see how the price adjusts itself after the clock. Says a lot about the algorithm time we live in :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
7 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,95%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16 min sittenOn the dot.
- ·22 min sitten · MuokattuUltimately, the price is probably driven by what the market expects going forward, and whether the company delivers better or worse than those expectations. I doubt that a "good piece of news" is necessarily enough if the market had already priced it in. And if the news just meets expectations, or disappoints even slightly, the stock can still be punished. So, in that sense, the market must also be willing to pay a higher and higher price every time new evidence for the case emerges. And right there, I think Novo will have a hard time with that in the short term. Not because the company is bad, but because confidence has been weakened, and because much of the positive news about obesity/GLP-1 has already been priced in before. I think the market will demand more than good headlines now. Real results will probably be needed: better earnings, better margins, less price pressure, stronger guidance and proof that the Wegovy pill doesn't just provide volume, but also profitable growth. Otherwise, it will be difficult to get the market to accept significantly higher prices again. It's probably also more about whether buyers are willing to be more and more aggressive and pay higher prices. And if many are sitting on large losses from the peak, the old levels can also become resistance, because people will want to get out when they get the chance. So I believe Novo can rise again (in the long term), but I don't think the market just gives them benefit of the doubt anymore. They need to prove the case in the numbers, not just in the narrative, and I doubt even more that they will do that in the short term. But well, what I'm saying is probably completely wrong, but we debate to become wiser, and that's just my actual statement on it·13 min sittenCouldn't agree more. I believe the stock is undervalued, but I also believe it's the numbers that should drive the price and not hype. Facts on the table, and we will get the price increases Novo deserves. The last 2 years have created great uncertainty, understandably. As the numbers improve, the stock will also be unleashed more, but Novo needs to show something more. That said, the stock HAS risen significantly recently and there will be investors who believe 300 kr is a good place to let it go.
- ·31 min sittenIt's trickling a bit early today, but it will, as usual, pick up in 12 min when US opens.
- ·1 t sittenExplanation requested: approx. 20 pct of the turnover of shares takes place on the American stock exchange. The rest takes place in DK. Why is it NOVO ADR that largely determines the price? Any good suggestions?
- ·1 t sittenIt's a bit ''funny'' to see how the price adjusts itself after the clock. Says a lot about the algorithm time we live in :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 24 | - | - | ||
| 93 | - | - | ||
| 96 | - | - | ||
| 100 | - | - | ||
| 72 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 711 451 | 2 711 451 | 0 | 0 |
| DCAR | 40 000 | 40 000 | 0 | 40 000 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 711 451 | 2 711 451 | 0 | 0 |
| DCAR | 40 000 | 40 000 | 0 | 40 000 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
UUTTA
7 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,95%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16 min sittenOn the dot.
- ·22 min sitten · MuokattuUltimately, the price is probably driven by what the market expects going forward, and whether the company delivers better or worse than those expectations. I doubt that a "good piece of news" is necessarily enough if the market had already priced it in. And if the news just meets expectations, or disappoints even slightly, the stock can still be punished. So, in that sense, the market must also be willing to pay a higher and higher price every time new evidence for the case emerges. And right there, I think Novo will have a hard time with that in the short term. Not because the company is bad, but because confidence has been weakened, and because much of the positive news about obesity/GLP-1 has already been priced in before. I think the market will demand more than good headlines now. Real results will probably be needed: better earnings, better margins, less price pressure, stronger guidance and proof that the Wegovy pill doesn't just provide volume, but also profitable growth. Otherwise, it will be difficult to get the market to accept significantly higher prices again. It's probably also more about whether buyers are willing to be more and more aggressive and pay higher prices. And if many are sitting on large losses from the peak, the old levels can also become resistance, because people will want to get out when they get the chance. So I believe Novo can rise again (in the long term), but I don't think the market just gives them benefit of the doubt anymore. They need to prove the case in the numbers, not just in the narrative, and I doubt even more that they will do that in the short term. But well, what I'm saying is probably completely wrong, but we debate to become wiser, and that's just my actual statement on it·13 min sittenCouldn't agree more. I believe the stock is undervalued, but I also believe it's the numbers that should drive the price and not hype. Facts on the table, and we will get the price increases Novo deserves. The last 2 years have created great uncertainty, understandably. As the numbers improve, the stock will also be unleashed more, but Novo needs to show something more. That said, the stock HAS risen significantly recently and there will be investors who believe 300 kr is a good place to let it go.
- ·31 min sittenIt's trickling a bit early today, but it will, as usual, pick up in 12 min when US opens.
- ·1 t sittenExplanation requested: approx. 20 pct of the turnover of shares takes place on the American stock exchange. The rest takes place in DK. Why is it NOVO ADR that largely determines the price? Any good suggestions?
- ·1 t sittenIt's a bit ''funny'' to see how the price adjusts itself after the clock. Says a lot about the algorithm time we live in :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 24 | - | - | ||
| 93 | - | - | ||
| 96 | - | - | ||
| 100 | - | - | ||
| 72 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 711 451 | 2 711 451 | 0 | 0 |
| DCAR | 40 000 | 40 000 | 0 | 40 000 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 711 451 | 2 711 451 | 0 | 0 |
| DCAR | 40 000 | 40 000 | 0 | 40 000 |